-+ 0.00%
-+ 0.00%
-+ 0.00%

Castle Biosciences shares rise; DecisionDx-Melanoma study in 1,868 SEER-linked patients shows 5-year melanoma-specific survival of 96.7% for Class 1A vs 70.0% for Class 2B in T1 tumors

Reuters·03/27/2026 13:07:05

Please log in to view news